Novavax Inc vs Plug Power Inc — how do they compare? Novavax Inc trades at $9.88 (market cap $1.68B), while Plug Power Inc trades at $2.19 (market cap $3.16B). The key difference: Plug Power Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | PLUG | |
|---|---|---|
Market Cap | $1.68B | $3.16B |
Sector | Health | Industrials |
52-Week High | $11.19 | $4.14 |
52-Week Low | $6.22 | $1.44 |
Enterprise Value | $1.26B | $4.03B |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
Plug Power (PLUG) trades at $2.26, up 4.15% today, but remains in a challenging fundamental position with persistent losses. The company shows modest revenue recovery to $710 million in 2025 but continues to report negative gross margins and substantial net losses. Technical indicators suggest a bullish short-term trend, while analyst sentiment remains divided with a $4.04 consensus price target representing significant upside potential from current levels.
While PLUG offers substantial upside based on analyst targets and growing electrolyzer demand, the investment carries high risk due to ongoing operational losses, negative cash flow, and heavy reliance on financing. The company's turnaround strategy shows early progress but requires sustained execution to achieve profitability amid competitive pressures in the hydrogen sector.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →